An attempt to make lipid-lowering therapy more effective in Hungary. The results of MULTI GAP 2010 and the PLUS Program

Archives of Medical Science

Volumn 7, Issue 5, 2011, Pages 760-766

  Mark, Laszlo ^a   Paragh, György ^b   Karadi, Istvan ^c   Reiber, Istvan ^d   Pados, Gyula ^e   Kiss, Zoltan ^f  

^a Pandy Kalman Bekes County Hospital   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d Saint George Hospital of Fejér County   (Hungary)

^e Szent Imre Hospital   (Hungary)

^f Baxter Hungary Kft   (Hungary)

Author keywords

Hypercholesterolaemia; LDL cholesterol; Prevention; Risk factors

Indexed keywords

ANTILIPEMIC AGENT; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; GENERAL PRACTITIONER; GOAL ATTAINMENT; HEALTH SURVEY; HUMAN; HUNGARY; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; MEDICAL SPECIALIST; PATIENT COMPLIANCE;

EID: 81555222778     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2011.25549     Document Type: Article

References (30)

1. World Health Report, WHO 2002 (http://www.who.int/whr/2002/en/).
2. Heart Health Charter. http://www.heartcharter.eu.
3. Rydén L, Martin J, Volqvartz S. The European Heart Health Charter: towards a healthier Europe. Eur J Cardiovasc Prev Rehabil 2007; 14: 355-6. (Pubitemid 46945557)
4. th International Symposium on Multiple Risk Factors in Cardiovascular Diseases: Prevention and Intervention-Health Policy, in Venice, Italy, on 25 October, 2008. Atheroscler Suppl 2009; 10: 3-21.
5. Yusuf S, Hawken S, Ounpuu S et al.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52. (Pubitemid 39208455)
6. Mark L. Paragh Gy, Karadi I, Reiber I, Pados Gy. Changes in attainment of lipid goals by general practitioners and specialists in patients at high cardiovascular risk in Hungary during 2004-2008. Arch Med Sci 2010; 6: 695-700.
7. Reiber I, Paragh Gy, Márk L. Status report from the abyss - the results from the Hungarian MULTI GAP 2009. Metabolizmus 2010; 8: 137-42.
8. Reiber I, Paragh GY, Márk L, Pados Gy. Becoming more focused therapeutic lipid patterns: results from the Hungarian MULTI GAP. Orv Hetil 2011; 152: 822-7.
9. The IV. Hungarian Cardiovascular Consensus Conference. Metabolizmus 2010; 8 Suppl A: 2-96.
10. Grundy SM, Cleeman JI, Merz CN, et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39. (Pubitemid 38924592)
11. Roberts WC. The rule of 5 and the rule of 7 in lipidlowering by statin drugs. Am J Cardiol 1997; 80: 106-7.
12. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93. (Pubitemid 36159355)
13. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91. (Pubitemid 351214285)
14. Yudkin JS, Richter B, Gale EA. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010; 53: 2079-85.
15. Packard CJ. Benefits of lipid regulation in acute coronary syndrome. Arch Med Sci 2010; 6 (Supl. 1A): S76-82.
16. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929-40.
17. Jánosi A, Östör E, Borbás S. et al. Data on secondary prevention of coronary artery disease in Hungary and some changes in the last ten years (EUROASPIRE 1995- 2005). Orvosi Hetilap 2010; 151: 1776-82.
18. Jozan P. Crisis and renewal in the epidemiological evolution after the second world war in Hungary. MTA Tarsadalomkutato Központ, Budapest 2008.
19. Li M, Ong KL, Tse HF, Cheung BMY. Utilization of lipid lowering medications among adults in the United States 1999-2006. Atherosclerosis 2010; 208: 456-60.
20. Farzadfar F, Finucane MM, Danaei G, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 30 million participants. Lancet 2011; 377: 578-86.
21. Capewell S, ES, Croft JB, et al. Cardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of America. Bull World Health Organiz 2010; 88: 120-30.
22. Waters DD, Brotons C, Chiang CW, et al.; Lipid Treatment Assessment Project 2 Investigators. Lipid Treatment Assessment Project 2. A Multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009; 120: 28-34.
23. Steinberg BA, Bhatt DL, Mehta S, et al. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J 2008; 156: 719-27.
24. Hermans MP, Cabezas MC, Strandberg T, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin 2010; 26: 445-54.
25. Katsiki N, Mikhailidis DP, Athyros VG, et al. Are we getting to lipid targets in real life? Arch Med Sci 2010; 6: 639-41.
26. Bugiardini R, Yan AT, Yan RT; the Canadian Acute Coronary Syndrome Registry I and II Investigators. Factors influencing underutilization of evidence-based therapies in women. Eur Heart J 2011; e-pub March 7. doi:10.1093/eurheartj/ehr027.
27. Rizzo M, Rini GB. Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia. Arch Med Sci 2011; 7: 5-7.
28. Gitt AK, Drexel H, Feely J, et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Cardiovasc Prev Rehabil 2011 Mar 10 [Epub ahead of print].
29. Simpson SH, Eurich DT, Majumdar SR, et al. A metaanalysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15.
30. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and longterm mortality after acute myocardial infarction. JAMA 2007; 297: 177-86. (Pubitemid 46089734)